DTC Biomarker Testing: Please Read the Fine Print

Posted by David Kriesman on May 24, 2018 11:17:42 AM

Pavankumar Anne, Sankalp Sethi and Matt Furlow co-authored this post with David Kriesman.

In oncology, we’re accustomed to “firsts” in the headlines—new discoveries, novel treatments and scientific breakthroughs offering hope to patients. Most newsworthy updates relate to emerging therapies, but on March 6, we saw a first in oncology diagnostic testing that has started making waves.


>
Read More

Oncology Experts Pinpoint the Key Drivers and Barriers of Biosimilar Adoption

Posted by ZS Editors on Aug 30, 2017 8:00:00 AM

Biosimilars are beginning to permeate the U.S. oncology market, but the floodgates aren’t exactly open. Despite their promise to expand treatment options and rein in cancer costs, biosimilars continue to face prescriber inexperience and other challenges that affect adoption levels. To execute an effective go-to-market strategy in the evolving cancer landscape, biosimilar manufacturers must contend with increasing competition, overcome patent disputes, and develop education programs for biosimilar-naïve stakeholders. Meanwhile, manufacturers of originator products will need to develop effective defense strategies in anticipation of biosimilar competition


>
Read More